ABSTRACT Objective This study aimed to investigate the mechanism and pharmacologically active compounds of Fufang Ejiao Jiang (FFEJJ) in the prevention and treatment of myelosuppression after chemotherapy (MAC) through a combination of serum metabolomics and network pharmacology. Methods Sprague Dawley rats were randomly assigned to three groups: the blank group, the model group, and the FFEJJ group (10.8 g/kg). A MAC rat model was induced using cyclophosphamide. Simultaneously with model establishment, rats were intragastrically administered once daily for 15 consecutive days. The routine blood parameters of the rats were measured, and pathological changes in the spleen and bone marrow were observed. Nontargeted serum metabolomics was employed to identify differential metabolites associated with MAC and their related pathways. Liquid chromatography-mass spectrometry (LC–MS) was used to analyze the chemical composition of FFEJJ, and its mechanism and pharmacologically active compounds in the treatment of MAC were further predicted using network pharmacology. Results FFEJJ significantly improved the hematopoietic function of bone marrow in the MAC model rats. Compared to the blank group, the model group exhibited obvious spleen injury and bone marrow disorder, with noticeable fatty infiltration in the bone marrow cavity. Following FFEJJ treatment, the condition of spleen tissue and bone marrow in MAC rats was significantly improved. Serum metabolomics analysis of endogenous metabolites identified 14 differential metabolites associated with the MAC mechanism in both positive and negative ion modes, primarily involving pathways such as aminoacyl-tRNA biosynthesis, primary bile acid biosynthesis, and unsaturated fatty acid biosynthesis. Using LC–MS, 31 components were identified in FFEJJ. Network pharmacology predictions suggest that the potential pharmacologically active compounds of FFEJJ in the treatment of MAC include apigenin, oleanolic acid, maslinic acid, and azelaic acid. The underlying mechanism may be partly associated with the phosphatidylinositol 3-kinase/serine-threonine kinase (PI3K-Akt) signaling pathway. Conclusion FFEJJ promotes hematopoietic recovery in MAC rats, likely by regulating endogenous metabolic disorders. Apigenin, oleanolic acid, maslinic acid, and azelaic acid are predicted to be multitarget active compounds, with PI3K-Akt signaling as a candidate pathway.

A 24 yuan cancer medicine becomes difficult to find Injectable cyclophosphamide, a chemotherapy medicine normally listed at about 24 yuan per vial in China, has been offered online for 600 to 650 yuan during a shortage that has disrupted hospital…

Piramal Pharma Solutions and NP2 are set to complete the cyclophosphamide development phase by next month, aiming to enhance cancer drug availability.

Piramal Pharma Solutions and NP2 will finalize the development phase of the generic cancer drug, Cyclophosphamide, in October 2026, enhancing supply security.

Piramal Pharma Solutions partners with NP2 to complete the development phase of cyclophosphamide, addressing critical shortages in cancer treatment.

Piramal Pharma Solutions and NP2 aim to finish developing cyclophosphamide, a crucial cancer treatment drug, next month in a bid to ensure a stable supply for patients.

An observational analysis showed a long-term OS benefit with Orca-T in adult patients undergoing allogeneic transplantation for hematologic malignancies.

Read the full paper: Differential heat shock protein transcript expression in mouse lower urinary tract (LUT) pathways in cyclophosphamide (CYP)-induced cystitis or repeated variate stress (RVS)

Background and objectives: Ganoderma species are widely used in traditional medicine for their immunomodulatory properties. However, systematic evaluations of indigenous Vietnamese taxa remain limited...

OPTIMUM shows sustained progression-free survival and overall survival improvement with risk-stratified extended therapy, supporting implementation of molecular diagnostics and tailored treatment in p...

Ewing sarcoma (ES) is a malignant bone tumor with high relapse rates, especially in multi-metastatic disease despite multimodal treatment. The role of maintenance therapy in ES remains undefined. We systematically reviewed clinical trial data to assess the feasibility and rationale for maintenance therapy in localized and metastatic disease, with the aim to help selecting drugs to introduce as maintenance therapy within the trial.

Cardiac involvement, which may remain clinically silent, is a major determinant of prognosis in eosinophilic granulomatosis with polyangiitis (EGPA), and remission induction generally requires glucocorticoids combined with cyclophosphamide or rituximab. In contrast, treatment selection may be challe …

UCL Discovery is UCL's open access repository, showcasing and providing access to UCL research outputs from all UCL disciplines.

A 59-year-old man presented with sore throat and cough, and chest computed tomography and bronchoscopy revealed airway stenosis. Four McAdam's criteria supported the diagnosis of relapsing polychondritis. High-dose prednisolone and cyclophosphamide improved symptoms and airway lesions, highlighting …

The standard 100 mg/kg dose of post-transplant cyclophosphamide (PTCy) for graft-versus-host disease (GVHD) prophylaxis after matched allogeneic stem cell transplantation (ASCT) is associated with imp...